Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Current Assets (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Current Assets for 8 consecutive years, with $49.4 million as the latest value for Q4 2025.

  • Quarterly Current Assets changed N/A to $49.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $49.4 million for FY2025, N/A changed from the prior year.
  • Current Assets for Q4 2025 was $49.4 million at Actinium Pharmaceuticals, down from $54.4 million in the prior quarter.
  • The five-year high for Current Assets was $118.3 million in Q2 2022, with the low at $49.4 million in Q4 2025.
  • Average Current Assets over 5 years is $83.0 million, with a median of $83.2 million recorded in 2021.
  • The sharpest move saw Current Assets soared 42.23% in 2022, then crashed 31.63% in 2025.
  • Over 5 years, Current Assets stood at $79.7 million in 2021, then soared by 39.11% to $110.9 million in 2022, then fell by 29.46% to $78.3 million in 2023, then rose by 1.61% to $79.5 million in 2024, then tumbled by 37.9% to $49.4 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $49.4 million, $54.4 million, and $61.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.